Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477010 | 1.00 | ROCK2 (0.40) | ROCK2CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL4497985 | 0.93 | ROCK2 (0.40) | ROCK2CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL4497979 | 0.93 | ROCK2 (0.40) | ROCK2CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL4499818 | 0.92 | ROCK2 (0.35) | ROCK2CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL4499823 | 0.92 | ROCK2 (0.35) | ROCK2CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL4505768 | 0.92 | MAOA (0.38) | ROCK2MAOAMAOBCASP3BRD4 | |
| SCHEMBL4505765 | 0.92 | MAOA (0.38) | ROCK2MAOAMAOBCASP3BRD4 | |
| SCHEMBL4495473 | 0.90 | KMT2A (0.41) | ROCK2NAMPT | |
| SCHEMBL4495466 | 0.90 | KMT2A (0.41) | ROCK2NAMPT | |
| SCHEMBL227119 | 0.89 | ROCK2 (0.45) | ROCK2CYP3A4CYP2C19BACE1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | ROCK2 392/4885CYP3A4 441/4885CYP2C19 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.